Skip to main content

Table 1 Clinical, biological, and radiological characteristics of patients admitted to ICU for hMPV infection and results of the univariate analysis comparing influenza and hMPV infected matched patients

From: Clinical significance of human metapneumovirus detection in critically ill adults with lower respiratory tract infections

Characteristics (n, %) or median (IQR)

hMPV infections

Total

(n=26)

hMPV infections

Unmatched

(n=10)

hMPV infections

Matched

(n=16)

Influenza infections

(n=16)

P*

Age

66 (56–74)

62 (42–66)

70 (58–76)

69 (54–75)

0.66

Gender (male)

15 (57.6)

6 (60.0)

9 (56.3)

11 (68.8)

0.46

Hematological malignancy

 Multiple myeloma

8 (30.8)

4 (40.0)

4 (25)

4 (25)

 

 Lymphoma

7 (26.9)

3 (30.0)

4 (25)

5 (31.3)

 

 Myeloproliferative disorder

3 (11.5)

2 (20.0)

1 (6.3)

1 (6.3)

0.84

 Acute leukemia

2 (7.7)

1 (10.0)

1 (6.3)

1 (6.3)

 

 Myelodysplastic syndrome

1 (3.8)

0 (0)

1 (6.3)

0 (0)

 

Other comorbidities

 Diabetes mellitus

7 (26.9)

0 (0)

7 (43.8)

7 (43.8)

1

 HIV infection

3 (11.5)

2 (20.0)

1 (6.3)

1 (6.3)

1

 Chronic respiratory failure

6 (23.1)

1 (10.0)

5 (31.3)

6 (37.5)

0.70

 Solid Cancer

3 (11.5)

1 (10.0)

2 (12.5)

0 (0)

0.14

 Steroids within the last 3 months

11 (42.3)

5 (50)

6 (37.5)

4 (25)

0.70

Symptoms

 SAPS 2 score

41 (37–58)

46 (40–58)

40 (36–60)

37 (30–47)

0.44

 Fever (>38°C)

23 (88.5)

8 (80.0)

15 (93.8)

14 (87.5)

0.50

 Shivers

9 (34.6)

3 (30.0)

6 (37.5)

4 (25)

0.40

 Flu-like syndrome

5 (19.2)

1 (10.0)

4 (25)

5 (31.3)

0.70

 ENT syndrome

8 (30.8)

2 (20.0)

6 (37.5)

3 (18.8)

0.20

 Cough

19 (73.1)

6 (60.0)

13 (81.3)

15 (93.8)

0.30

 Sputum

9 (34.6)

2 (20.0)

7 (43.8)

6 (37.5)

0.70

 Dyspnea

24 (92.3)

8 (80.0)

16 (100)

15 (93.8)

0.30

 Wheezing

4 (15.4)

2 (20.0)

2 (12.5)

5 (31.3)

0.20

 Thoracic pain

1 (3.8)

0 (0.0)

1 (6.3)

2 (12.5)

0.50

 Digestive symptoms

7 (26.9)

3 (30.0)

4 (25)

2 (12.5)

0.40

Biology characteristics

 Neutropenia

7 (26.9)

4 (40.0)

3 (18.8)

0 (0)

0.07

 Lymphopenia

19 (73.1)

9 (90.0)

10 (62.5)

10 (62.5)

1

 Chest X ray performed

25 (96.2)

10 (100)

15 (93.8)

16 (100)

 

 Normal

4 (16.0) **

2 (20)

2 (13.3)**

2 (12.5)

1

 Alveolar syndrome

 Interstitial syndrome

6 (24.0) **

20 (80.0) **

2 (20)

6 (60)

4 (26.7)**

14 (93.3)**

4 (25)

8 (50)

1

0.25

 Four quadrants involved

12 (48.0) **

2 (20)

10 (66.7)**

3.(18.8)

0.04

 Pleural effusion

5 (20.0) **

3 (30)

2 (13.3)**

0 (0)

0.59

 Ct scan performed

14 (53.8)

6 (60)

8 (50)

5 (31.3)

 

 Ground glass opacities

10 (66.8) **

4 (66.7)**

6 (75)**

3 (60)**

0.04

 Alveolar consolidation

9 (60.0) **

4 (66.7)**

5 (62.5)**

3 (60)**

0.72

 Septal thickening

3 (20.0) **

2 (33.3)**

1 (12.5)**

2 (40)**

0.76

 Nodular lesions

9 (60.0) **

2 (33.3)**

7 (87.5)**

5 (100)**

0.91

 Crazy paving

3 (20.0) **

2 (33.3)**

1 (12.5)**

2 (40)**

0.76

 Bronchial lesions

2 (13.3) **

0 (0)**

2 (25)**

4 (80)**

0.04

Coinfections

 Viral

8 (30.8)

8 (80)

0 (0)

3 (18.8)

 Bacterial

14 (53.8)

5 (50)

9 (56.3)

3 (18.8)

0.07

ICU management and outcomes

 Symptoms duration before ICU admission

7 (2–11)

2 (1–7)

9 (6–15)

3 (2–5)

< 0.001

 Mechanical ventilation

10 (38.5)

4 (40)

6 (37.5)

7 (43.8)

0.72

 ARDS

5 (19.2)

2 (20)

3 (18.8)

5 (31.2)

0.68

 Vasopressor support

11 (42.3)

7 (70)

4 (25)

9 (56.3)

0.07

 Renal replacement therapy

4 (15.4)

2 (20)

2 (12.5)

4 (25)

0.36

 Antibiotic duration

11 (8–15)

11 (8–13)

8 (2–18)

8 (7–14)

0.85

 Hospital length of stay (days)

17 (9–27)

18 (11–33)

17 (8–25)

10 (7–21)

0.16

 ICU length of stay (days)

5 (3–8)

6 (3–8)

7 (5–11)

5 (3–12)

0.95

 Hospital mortality

8 (30.8)

5 (50)

3 (18.6)

9 (56)

0.03

  1. ENT Ear, Nose and Throat, ICU Intensive care unit, HIV Human immunodeficiency virus, hMPV Human metapneumovirus, LRTIs Low respiratory tract infections, SAPS II Simplified Acute Physiology Score
  2. *Univariate analysis compares the hMPV and the influenza infected matched groups
  3. **Percentages are calculated considering the actual number of exams performed